Forecast: Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry in Japan

The forecasted data for business enterprise expenditure on R&D in Japan's pharmaceutical industry shows a gradual increase from 2024 to 2028, starting at 11.79% of BERD in manufacturing and rising to 12.21%. Compared to 2023, where the data is assumed to be marginally lower, this marks a steady growth trend.

- Year-on-year increase is approximately 1% to 1.1% annually for each year in the forecasting period.

- The compound annual growth rate (CAGR) over five years indicates a consistent positive trend, reflecting sustained investment in R&D within the industry.

Future trends to watch for include the impact of emerging technologies and the evolving regulatory landscape, which may influence the pace and direction of R&D expenditure. Additionally, the growing emphasis on precision medicine and biologics could further bolster R&D activities.